Induction of complement attack on human cells by Gal(alpha 1,3)Gal xenoantigen expression as a gene therapy approach to cancer

Gene Therapy

Volumn 6, Issue 6, 1999, Pages 1073-1083

  Jager U ^a   Takeuchi, Y ^a   Porter, C D ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

( 1,3)galactosyl transferase; Cancer gene therapy; Complement mediated lysis; Gal( 1,3)Gal; Hyperacute rejection

Indexed keywords

COMPLEMENT; GALACTOSE; GALACTOSYLTRANSFERASE; GLYCOSYLPHOSPHATIDYLINOSITOL; REGULATOR PROTEIN; VIRUS VECTOR;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CANCER; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CYTOLYSIS; ENDOTHELIUM CELL; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS;

ANTIGENS, HETEROPHILE; COMPLEMENT SYSTEM PROTEINS; DISACCHARIDES; FLOW CYTOMETRY; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; NEOPLASMS; RETROVIRIDAE; TUMOR CELLS, CULTURED;

ANIMALIA; PRIMATES; UNIDENTIFIED RETROVIRUS;

EID: 0032981795     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300934     Document Type: Article

References (34)

1. Platt JL et al. Immunopathology of hyperacute xenograft rejection in a swine-to-primate model. Transplantation 1991; 52: 214-220.
2. Dalmasso AP et al. Mechanism of complement activation in the hyperacute rejection of porcine organs transplanted into primate recipients. Am J Pathol 1992; 140: 1157-1166.
3. Sandrin MS, Vaughan HA, Dabkowski PL, McKenzie IFC. Antipig IgM antibodies in human serum react predominantly with Gal(alpha1,3)Gal epitopes. Proc Natl Acad Sci USA 1993; 90: 11391-11395.
4. Vaughan HA, Loveland BE, Sandrin MS. Gal-alpha(1,3)-Gal is the major xenoepitope expressed on pig endothelial cells recognized by naturally occurring cytotoxic human antibodies. Transplantation 1994; 58: 879-882.
5. Vaughan HA, Dabkowski PL, McKenzie IFC, Sandrin MS. Biochemical analysis of pig xenoantigens detected by human antibodies. Transplantation Proc 1993; 25: 2919-2920.
6. Paulson JC, Colley KJ. Glycosyltransferases: structure, localization, and control of cell type-specific glycosylation. J Biol Chem 1989; 264: 17615-17618.
7. Galili U et al. Evolutionary relationship between the natural anti-Gal antibody and the Gal alpha1-3 Gal epitope in primates. Proc Natl Acad Sci USA 1987; 84: 1369-1373.
8. Galili U et al. Interaction between human natural anti-alpha-gal-actosyl immunoglobulin G and bacteria of the human flora. Infect Immunol 1988; 56: 1730-1737.
9. Galili U. Interaction of the natural anti-Gal antibody with alpha-galactosyl epitopes: a major obstacle for xenotransplantation in humans. Immunol Today 1993; 14: 480-482.
10. Galili U et al. One percent of human circulating B lymphocytes are capable of producing the natural anti-Gal antibody. Blood 1993; 82: 2485-2493.
11. Galili U, Rachmilewitz EA, Peleg A, Flechner I. A unique natural human IgG antibody with anti-alpha-galactosyl specificity. J Exp Med 1984; 160: 1519-1531.
12. McMorrow IM, Comrack CA, Sachs DH, DerSimonian H. Heterogeneity of human anti-pig natural antibodies cross-reactive with the Gal(alpha1,3)Galactose epitope. Transplantation 1997; 64: 501-510.
13. Takeuchi Y et al. Sensitization of cells and retroviruses to human serum by (alpha 1-3) galactosyltransferase. Nature 1996; 379: 85-88.
14. Reed DJ et al. Alteration of glycosylation renders HIV sensitive to inactivation by normal human serum. J Immunol 1997; 159: 4356-4361.
15. Sandrin MS et al. Enzymatic remodelling of the carbohydrate surface of a xenogeneic cell substantially reduces human antibody binding and complement-mediated cytolysis. Nature Med 1995; 1: 1261-1267.
16. Osman N, McKenzie IFC, Mouhtouris E, Sandrin MS. Switching amino-terminal cytoplasmic domains of alpha(1,2)fucosyl transferase and alpha(1,3)galactosyl transferase alters the expression of H substance and Gal-alpha(1,3)-Gal. J Biol Chem 1996; 271: 33105-33109.
17. Rother RP et al. A novel mechanism of retrovirus inactivation in human serum mediated by anti-α-galactosyl natural antibody. J Exp Med 1995; 182: 1345-1355.
18. Cairns T et al. Inhibition of the pig to human xenograft reaction using soluble GALα1-3GAL and GALβ1-3GALβ1-GlcNAc. Transplantation 1995; 60: 1202-1207.
19. Morgan BP, Meri S. Membrane proteins that protect against complement lysis. Springer Semin Immunopathol 1994; 15: 369-396.
20. Cozzi E, White DJ. The generation of transgenic pigs as potential organ donors for humans. Nature Med 1995; 1: 964-966.
21. McCurry KR et al. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nature Med 1995; 1: 423-127.
22. Collins BH et al. Cardiac xenografts between primate species provide evidence for the importance of the alpha-galactosyl determinant in hyperacute rejection. J Immunol 1995; 154: 5500-5510.
23. McMorrow IM et al. Relationship between ABO blood group and levels of Gal-alpha1,3-Galactose-reactive human immunoglobulin G. Transplantation 1997; 64: 546-549.
24. Maenpaa A et al. Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas. Am J Pathol 1996; 148: 1139-1152.
25. Bjorge L et al. Complement-regulatory proteins in ovarian malignancies. Int J Cancer 1997; 70: 14-25.
26. LaTemple DC, Henion TR, Anaraki F, Galili U. Synthesis of alpha-galactosyl epitopes by recombinant alpha1,3galactosyl transferase for opsonization of human tumor cell vaccines by anti-galactose. Cancer Res 1996; 56: 3069-3074.
27. Galili U, LaTemple DC. Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity. Immunol Today 1997; 18: 281-285.
28. Wang L, Anaraki F, Henion TR, Galili U. Variations in activity of the human natural anti-Gal antibody in young and elderly populations. J Gerontol 1995; 50A: M227-M233.
29. Patel PM et al. Generation of interleukin-2-secreting melanoma cell populations from resected metastatic tumors. Hum Gene Ther 1994; 5: 577-584.
30. Strahan KM et al. cDNA sequence and chromosome location of pig alpha1,3 galactosyltransferase. Immunogenetics 1995; 41: 101-105.
31. Dranoff G et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.
32. Cosset F-L et al. High titre packaging cells producing recombinant retroviruses resistant to human serum. J Virol 1995; 69: 7430-7436.
33. Davies A et al. CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of complement membrane attack complex in homologous cells. J Exp Med 1989; 170: 637-654.
34. Armitage P, Berry G. Statistical Methods in Medical Research, 2nd edn. Blackwell Scientific: Oxford, 1987.